{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T13:31:54Z","timestamp":1789997514918,"version":"4.0.1"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008363","name":"Kr\u00e6ftens Bek\u00e6mpelse","doi-asserted-by":"publisher","award":["R309-A17906"],"award-info":[{"award-number":["R309-A17906"]}],"id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","gynecologiconcology-online.net","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.ygyno.2024.02.013","type":"journal-article","created":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T00:30:19Z","timestamp":1708475419000},"page":"108-115","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Risk of borderline ovarian tumors after fertility treatment - Results from a Danish cohort of infertile women"],"prefix":"10.1016","volume":"185","author":[{"given":"Anna Kj\u00e6r","family":"Kristensen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarissa Lima Brown","family":"Frandsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bugge","family":"N\u00f8hr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob Hansen","family":"Viuff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Hargreave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Frederiksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne K.","family":"Kj\u00e6r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2024.02.013_bb0005","doi-asserted-by":"crossref","first-page":"10952","DOI":"10.18632\/aging.102497","article-title":"Global, regional, and national prevalence and disability-adjusted life-years for infertility in 195 countries and territories, 1990-2017: results from a global burden of disease study, 2017","volume":"11","author":"Sun","year":"2019","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.ygyno.2024.02.013_bb0010","author":"European Society of Human Reproduction and Embryology"},{"key":"10.1016\/j.ygyno.2024.02.013_bb0015","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1196\/annals.1365.022","article-title":"Fertility drugs and gynecologic cancer","volume":"1092","author":"Kanakas","year":"2006","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.ygyno.2024.02.013_bb0020","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3389\/fendo.2019.00313","article-title":"Do the fertility drugs increase the risk of cancer? A review study","volume":"10","author":"Momenimovahed","year":"2019","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.ygyno.2024.02.013_bb0025","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0015-0282(16)58020-0","article-title":"Human menopausal gonadotropin and the risk of epithelial ovarian cancer","volume":"65","author":"Shushan","year":"1996","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.ygyno.2024.02.013_bb0030","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1093\/oxfordjournals.aje.a116429","article-title":"Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. IV. The pathogenesis of epithelial ovarian cancer. Collaborative Ovarian Cancer Group","volume":"136","author":"Whittemore","year":"1992","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.ygyno.2024.02.013_bb0035","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.fertnstert.2012.12.029","article-title":"In vitro fertilization and risk of breast and gynecologic cancers: a retrospective cohort study within the Israeli Maccabi healthcare services","volume":"99","author":"Brinton","year":"2013","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.ygyno.2024.02.013_bb0040","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b249","article-title":"Use of fertility drugs and risk of ovarian cancer: Danish population based cohort study","volume":"338","author":"Jensen","year":"2009","journal-title":"BMJ."},{"key":"10.1016\/j.ygyno.2024.02.013_bb0045","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/IGC.0b013e318277608b","article-title":"Meta-analysis on the possible association between in vitro fertilization and cancer risk","volume":"23","author":"Li","year":"2013","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2024.02.013_bb0050","first-page":"CD008215","article-title":"Risk of ovarian cancer in women treated with ovarian stimulating drugs for infertility","volume":"6","author":"Rizzuto","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ygyno.2024.02.013_bb0055","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/humupd\/dms051","article-title":"Controlled ovarian hyperstimulation for IVF: impact on ovarian, endometrial and cervical cancer--a systematic review and meta-analysis","volume":"19","author":"Siristatidis","year":"2013","journal-title":"Hum. Reprod. Update"},{"key":"10.1016\/j.ygyno.2024.02.013_bb0060","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.bpobgyn.2016.08.007","article-title":"Pathology of borderline and invasive cancers","volume":"41","author":"Prat","year":"2017","journal-title":"Best Pract. Res. Clin. Obstet. Gynaecol."},{"key":"10.1016\/j.ygyno.2024.02.013_bb0065","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1634\/theoncologist.2012-0139","article-title":"Diagnosis, treatment, and follow-up of borderline ovarian tumors","volume":"17","author":"Fischerova","year":"2012","journal-title":"Oncologist."},{"key":"10.1016\/j.ygyno.2024.02.013_bb0070","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1002\/ijc.32864","article-title":"Risk of specific types of ovarian cancer after borderline ovarian tumors in Denmark: A nationwide study","volume":"147","author":"Hannibal","year":"2020","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ygyno.2024.02.013_bb0075","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s10654-019-00540-3","article-title":"Assisted reproductive technology and risk of ovarian cancer and borderline tumors in parous women: a population-based cohort study","volume":"34","author":"Lundberg","year":"2019","journal-title":"Eur. J. Epidemiol."},{"key":"10.1016\/j.ygyno.2024.02.013_bb0080","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1056\/NEJM199409223311204","article-title":"Ovarian tumors in a cohort of infertile women","volume":"331","author":"Rossing","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2024.02.013_bb0085","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1093\/jnci\/djaa163","article-title":"Long-term risk of ovarian cancer and borderline tumors after assisted reproductive technology","volume":"113","author":"Spaan","year":"2021","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2024.02.013_bb0090","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.ygyno.2013.01.027","article-title":"In vitro fertilization is associated with an increased risk of borderline ovarian tumours","volume":"129","author":"Stewart","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2024.02.013_bb0095","article-title":"Risks of ovarian, breast, and corpus uteri cancer in women treated with assisted reproductive technology in Great Britain, 1991-2010: data linkage study including 2.2 million person years of observation","volume":"362","author":"Williams","year":"2018","journal-title":"BMJ."},{"key":"10.1016\/j.ygyno.2024.02.013_bb0100","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1093\/humrep\/deu297","article-title":"Risk for borderline ovarian tumours after exposure to fertility drugs: results of a population-based cohort study","volume":"30","author":"Bjornholt","year":"2015","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.ygyno.2024.02.013_bb0105","series-title":"Guidelines for ATC Classification and DDD Assignment 2019","first-page":"20","year":"2019"},{"key":"10.1016\/j.ygyno.2024.02.013_bb0110","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/EDE.0b013e3181ce9f08","article-title":"Estimating population distributions when some data are below a limit of detection by using a reverse Kaplan-Meier estimator","volume":"21","author":"Gillespie","year":"2010","journal-title":"Epidemiology."},{"key":"10.1016\/j.ygyno.2024.02.013_bb0115","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/j.fertnstert.2013.02.010","article-title":"Fertility drug use and the risk of ovarian tumors in infertile women: a case-control study","volume":"99","author":"Asante","year":"2013","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.ygyno.2024.02.013_bb0120","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1080\/09513590701350341","article-title":"Ovulation induction treatment and risk of borderline ovarian tumors","volume":"23","author":"Cusido","year":"2007","journal-title":"Gynecol. Endocrinol."},{"key":"10.1016\/j.ygyno.2024.02.013_bb0125","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/1055-9965.EPI-12-0426","article-title":"Use of fertility drugs and risk of ovarian cancer: results from a U.S.-based case-control study","volume":"21","author":"Kurta","year":"2012","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"10.1016\/j.ygyno.2024.02.013_bb0130","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0015-0282(98)00337-9","article-title":"Ovarian stimulation and borderline ovarian tumors: a case-control study","volume":"70","author":"Mosgaard","year":"1998","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.ygyno.2024.02.013_bb0135","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1093\/aje\/kwh315","article-title":"A case-control study of ovarian cancer in relation to infertility and the use of ovulation-inducing drugs","volume":"160","author":"Rossing","year":"2004","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.ygyno.2024.02.013_bb0140","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1093\/humrep\/des031","article-title":"Cancer morbidity in a cohort of 9175 Finnish women treated for infertility","volume":"27","author":"Yli-Kuha","year":"2012","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.ygyno.2024.02.013_bb0145","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s00404-021-06355-6","article-title":"Subfertility, use of fertility treatments and BRCA mutation status and the risk of ovarian cancer","volume":"306","author":"Lerner-Geva","year":"2022","journal-title":"Arch. Gynecol. Obstet."},{"key":"10.1016\/j.ygyno.2024.02.013_bb0150","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1093\/aje\/155.3.217","article-title":"Infertility, fertility drugs, and ovarian cancer: a pooled analysis of case-control studies","volume":"155","author":"Ness","year":"2002","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.ygyno.2024.02.013_bb0155","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1006\/gyno.1997.4928","article-title":"Treatment for fertility and risk of ovarian tumors of borderline malignancy","volume":"68","author":"Parazzini","year":"1998","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2024.02.013_bb0160","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1158\/1055-9965.EPI-16-0809","article-title":"Cancer risk in women treated with fertility drugs according to parity status-A registry-based cohort study","volume":"26","author":"Reigstad","year":"2017","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"10.1016\/j.ygyno.2024.02.013_bb0165","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.fertnstert.2008.01.073","article-title":"Ovarian epithelial neoplasia after hormonal infertility treatment: long-term follow-up of a historical cohort in Sweden","volume":"91","author":"Sanner","year":"2009","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.ygyno.2024.02.013_bb0170","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1093\/humrep\/der322","article-title":"Risk of borderline and invasive ovarian tumours after ovarian stimulation for in vitro fertilization in a large Dutch cohort","volume":"26","author":"van Leeuwen","year":"2011","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.ygyno.2024.02.013_bb0175","author":"Statistics Denmark"},{"key":"10.1016\/j.ygyno.2024.02.013_bb0180","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.ygyno.2017.01.002","article-title":"Parity, infertility, oral contraceptives, and hormone replacement therapy and the risk of ovarian serous borderline tumors: a nationwide case-control study","volume":"144","author":"Rasmussen","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2024.02.013_bb0185","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/aogs.14013","article-title":"Borderline ovarian tumors in Denmark 1997-2018: time trends in incidence by histology, age and educational level","volume":"100","author":"Baandrup","year":"2021","journal-title":"Acta Obstet. Gynecol. Scand."},{"key":"10.1016\/j.ygyno.2024.02.013_bb0190","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0140-6736(71)92335-X","article-title":"Incessant ovulation--a factor in ovarian neoplasia?","volume":"2","author":"Fathalla","year":"1971","journal-title":"Lancet."},{"key":"10.1016\/j.ygyno.2024.02.013_bb0195","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1124\/jpet.104.080051","article-title":"The evolution of in vitro fertilization: integration of pharmacology, technology, and clinical care","volume":"313","author":"Feinberg","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ygyno.2024.02.013_bb0200","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1093\/humrep\/des082","article-title":"Hormonal and molecular characterization of follicular fluid, cumulus cells and oocytes from pre-ovulatory follicles in stimulated and unstimulated cycles","volume":"27","author":"de los Santos","year":"2012","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.ygyno.2024.02.013_bb0205","first-page":"40","article-title":"Is estradiol a genotoxic mutagenic carcinogen?","volume":"21","author":"Liehr","year":"2000","journal-title":"Endocr. Rev."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825824001094?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825824001094?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T08:35:43Z","timestamp":1732610143000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825824001094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":41,"alternative-id":["S0090825824001094"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2024.02.013","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of borderline ovarian tumors after fertility treatment - Results from a Danish cohort of infertile women","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2024.02.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}